AZ's Fasenra Hits First Hurdle Hard In COPD Study
AstraZeneca’s bid to expand its respiratory biologic Fasenra from asthma into the chronic obstructive pulmonary disease space has been hurt by a Phase III failure but the company is holding its horses until the results of another large late-stage trial come in before the end of this quarter.
You may also be interested in...
AstraZeneca has failed to show that its LAMA/LABA combo Bevespi Aerosphere is better than GSK’s Anoro Ellipta in a Phase IIIb study, a result “inconsistent” with previous data, but not surprising according to experts.
Potential ASCO readouts and the recent setback for Fasenra in COPD will feature in AstraZeneca’s first quarter earnings presentation next week.
Following FDA approval, AstraZeneca believes that despite reaching the market after GlaxoSmithKline’s Nucala and Teva’s Cinqair, Fasenra's strong clinical package, convenient dosing and very competitive pricing will make it the leading biologic for severe asthma.